Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 12,637 | 3,998 | 3,137 | 5,755 | 6,355 |
| TOTAL | $14,362 | $5,047 | $7,813 | $10,208 | $10,223 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $14,362 | $5,047 | $7,813 | $10,208 | $10,223 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,099 | 3,395 | 4,107 | 1,293 | 1,926 |
| Accrued Expenses | 1,292 | 663 | 763 | 2,986 | 1,639 |
| TOTAL | $5,391 | $4,057 | $4,870 | $4,279 | $3,565 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,907 | 2,740 | 6,297 | 13,680 | 0 |
| TOTAL | $1,907 | $2,740 | $6,297 | $13,680 | $N/A |
| Total Liabilities | $7,298 | $6,797 | $11,167 | $17,959 | $3,565 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 13,797 | 13,054 | 11,171 | 11,011 | 10,262 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -128,985 | -116,346 | -111,326 | -110,259 | -88,046 |
| TOTAL | $7,064 | $-1,751 | $-3,354 | $-7,751 | $6,658 |
| Total Liabilities And Equity | $14,362 | $5,046 | $7,813 | $10,208 | $10,223 |